Testing Services

The Institute of Pharmacy and Guangzhou Aiqixi Pharmaceutical Technology Co., Ltd. signed a cooperative research and development agreement for Class 1 chemical drug IMBZ18g

Testing Services

● On July 6, 2021, the Institute of Pharmaceutical Biotechnology of the Chinese Academy of Medical Sciences (hereinafter referred to as the "Institute of Pharmacy") and Guangzhou Aiqixi Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Aiqixi Pharmaceutical") officially signed a cooperative research and development agreement for IMBZ18g, a class 1 chemical drug. Vice Director Che Yongsheng, Vice Director Li Zhuorong, Director Sheng Fengnian of the Scientific Research Department, Project Leader Song Danqing and You Xuefu, as well as Chairman Lin Lidong and General Manager Feng Shengxi of Aiqixi Pharmaceutical, led by the Institute of Pharmacy, attended the signing ceremony and had a friendly and enthusiastic discussion. The meeting was presided over by Vice Director Li Zhuorong.

Testing Services

● On July 6, 2021, the Institute of Pharmaceutical Biotechnology of the Chinese Academy of Medical Sciences (hereinafter referred to as the "Institute of Pharmacy") and Guangzhou Aiqixi Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Aiqixi Pharmaceutical") officially signed a cooperative research and development agreement for IMBZ18g, a class 1 chemical drug. Vice Director Che Yongsheng, Vice Director Li Zhuorong, Director Sheng Fengnian of the Scientific Research Department, Project Leader Song Danqing and You Xuefu, as well as Chairman Lin Lidong and General Manager Feng Shengxi of Aiqixi Pharmaceutical, led by the Institute of Pharmacy, attended the signing ceremony and had a friendly and enthusiastic discussion. The meeting was presided over by Vice Director Li Zhuorong.

Testing Services

● Vice Director Che Yongsheng and Chairman Lin Lidong jointly signed a cooperative research and development agreement for Class 1 chemical drug IMBZ18g on behalf of both parties.

● Vice Director Che Yongsheng and Chairman Lin Lidong jointly signed a cooperative research and development agreement for Class 1 chemical drug IMBZ18g on behalf of both parties.